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Although the immediate-early proteins of both herpes simplex virus (HSV) and cytomegalovirus (CMV) are
known to modify promyelocytic leukemia (PML) (ND10) bodies in the nucleus of the host cell, it has been
unclear whether lytic infection with gamma herpesviruses induces a similar effect. The PML protein is induced
by interferon, involved in major histocompatibility complex class I presentation, and necessary for certain
types of apoptosis. Therefore, it is likely that PML bodies function in an antiviral capacity. SUMO-1 modifi-
cation of PML is known to be required for the formation of PML bodies. To examine whether Epstein-Barr
virus (EBV) lytic replication interferes with PML bodies, we expressed the EBV immediate-early genes BZLF1
(Z) and BRLF1 (R) in EBV-positive cell lines and examined PML localization. Both Z and R expression
resulted in PML dispersion in EBV-positive cells. Z but not R expression is sufficient to disrupt PML bodies
in EBV-negative cell lines. We show that dispersion of PML bodies by Z requires a portion of the transcrip-
tional activation domain of Z but not the DNA-binding function. As was previously reported for the HSV-1
ICP0 and CMV IE1 proteins, Z reduces the amount of SUMO-1-modified PML. We also found that Z itself is
SUMO-1 modified (through amino acid 12) and that Z competes with PML for limiting amounts of SUMO-1.
These results suggest that disruption of PML bodies is important for efficient lytic replication of EBV.
Furthermore, Z may potentially alter the function of a variety of cellular proteins by inhibiting SUMO-1
modification.
Epstein-Barr virus (EBV) is a member of the human her-
pesvirus family of viruses and infects approximately 90% of the
world’s population. EBV is responsible for the clinical syn-
drome infectious mononucleosis (66) and is found in various
tumors, including nasopharyngeal carcinoma and Burkitt’s
lymphoma (66, 88). Upon infection of the host, EBV initially
replicates within epithelial cells in the oropharynx (44, 52, 66,
71) and subsequently infects B cells trafficking through the
pharynx. In B cells, the virus usually converts to a latent form
and persists indefinitely in the host (44, 52, 66, 71). During
latency, only a small subset of EBV-encoded proteins are ex-
pressed. Occasionally, the latent virus within B cells switches
back to the lytic mode of replication (66). Virus released from
B cells then reinfects pharyngeal epithelial cells, resulting in
the secretion of infectious virus into the saliva.
The first EBV genes expressed during the lytic form of viral
replication are the immediate-early genes BZLF1 (Z) and
BRLF1 (R) (44). The Z and R proteins function as transcrip-
tional activators and induce expression of the next tier of EBV
genes, the early genes (14, 15, 16, 28, 32, 33, 36, 41, 53, 64, 67,
68, 75, 78). The early genes encode the viral proteins required
for EBV DNA replication (44). Viral DNA replication is fol-
lowed by EBV late-gene expression and packaging of the virus
(44).
Viruses often manipulate their host’s cellular environment
in order to create favorable conditions for viral replication and
survival. Virally induced changes include modulation of host
cell cycle progression, signal transduction cascades, and tran-
scriptional functions, among others. Notably, a number of vi-
ruses, including herpes simplex virus type 1 (HSV-1) and cy-
tomegalovirus (CMV), disperse nuclear structures known as
promyelocytic leukemia (PML, also called nuclear domain 10
[ND10]) bodies. The viral proteins responsible for PML body
dispersion in HSV-1 and CMV are the immediate-early pro-
teins HSV-1 ICP0 and CMV IE1 (3, 4, 23, 40, 46, 57). Inter-
estingly, ICP0 mutants (containing alterations within the
RING finger) which cannot disperse PML bodies also fail to
activate gene expression and cannot replicate efficiently, sug-
gesting a link between PML bodies and viral replication (21).
PML-containing nuclear bodies are made up of several pro-
teins, including CREB-binding protein (CBP), Sp100, Rb,
Daxx, ISG20, and the small ubiquitin-related modifier
SUMO-1 (6, 31, 48, 74, 87). However, only the PML protein is
known to be absolutely essential for the formation of these
bodies (86). The PML protein was initially identified in pa-
tients with acute PML who harbored a translocation resulting
in a fusion protein between the retinoic acid receptor a and
PML protein (18, 30, 34, 38, 58, 62). This RARa-PML fusion
protein prevents PML protein from localizing in nuclear bod-
ies (20, 45, 80), which normally appear as 10 to 30 discrete dots
(depending upon cell type) within the nucleus. Treatment with
retinoic acid leads to degradation of the RARa-PML fusion
protein, proper PML protein localization, and cancer remis-
sion (34, 58). The wild-type PML protein is also involved in
major histocompatibility complex (MHC) class I presentation
(85) and is required for certain types of apoptosis (10, 24, 37,
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51, 63, 77, 79, 87). In addition, PML protein expression is
induced by type I and II interferons (27, 50). Therefore, it is
likely that PML protein functions in an antiviral as well as
antitumor capacity.
The PML protein was recently shown to be covalently mod-
ified by the SUMO-1 protein (8, 60, 72). SUMO-1 is an 11.5-
kDa protein that is homologous to ubiquitin (8, 39, 49, 54, 56,
70); however, SUMO-1 does not function in the same manner
as ubiquitin. SUMO-1 becomes covalently attached to a variety
of proteins, including PML, RanGAP1, and IkB, and serves to
localize and/or stabilize these proteins (8, 17, 55, 60, 72). The
SUMO-1 modification of PML protein is required for its lo-
calization to nuclear bodies (60, 86). SUMO-1 modification of
PML protein is also required for the localization of several
other proteins, including Sp100, Daxx, CBP, and ISG20, into
PML bodies (86).
HSV-1 and CMV were both recently shown to disrupt PML
bodies by inhibiting the formation of SUMO-1-modified spe-
cies of PML protein (13, 22, 59). Interestingly, the CMV im-
mediate-early protein IE1 (as well as the IE2 protein) is itself
SUMO-1 modified (35, 59). The ability of both alphaherpes-
viruses (HSV) and betaherpesviruses (CMV) to disperse PML
bodies in the host cell suggests that this function may be uni-
versally important for efficient herpesvirus replication, includ-
ing gammaherpesviruses such as EBV. However, to our knowl-
edge the effect of lytic EBV infection on PML bodies has not
been previously examined, probably due to the difficulty of
inducing efficient lytic EBV infection in vitro.
In this study, we have examined the ability of lytic EBV
infection to disperse PML bodies. We show that induction of
the lytic form of EBV infection using either expression vectors
for Z or R or an adenovirus vector that expresses Z leads to
dispersion of PML bodies in EBV-positive cells. In EBV-neg-
ative cells, expression of the immediate-early protein Z alone
but not R alone is sufficient to disperse PML bodies. The
dispersal of PML bodies is coincident with the loss of high-
molecular-weight (SUMO-1-modified) isoforms of PML bod-
ies. In transfection assays, we show that the first 86 amino acids
of Z (which encode the transcriptional activation domain as
well as a replication function) are required for PML body
dispersion. We have also discovered that Z itself is SUMO-1
modified at amino acid 12. Additionally, we demonstrate that
Z is able to outcompete PML bodies for SUMO-1 modification
and that competition for SUMO-1 modification requires the
lysine at amino acid 12. The disruption of PML bodies by all
classes of herpesviruses suggests that this function is important
for efficient lytic replication.
MATERIALS AND METHODS
Cell lines. DG75 is an EBV-negative Burkitt’s lymphoma cell line, and Akata
is an EBV-positive Burkitt’s lymphoma cell line. B-cell lines were maintained in
RPMI 1640 medium supplemented with 10% fetal calf serum. A549 is a human
lung carcinoma line. HeLa is a cervical carcinoma cell line. D98/HE-R-1 is an
EBV-positive epithelial cell line formed by the fusion of an HeLa subclone (D98)
with the EBV-positive Burkitt’s lymphoma cell line P3HR/1 (29). Epithelial cell
lines were maintained in Dulbecco’s modified Eagle’s medium H supplemented
with 10% fetal calf serum.
Akata cell induction. Akata cells, at 2 3 106 cells/ml, were incubated in the
presence or absence of 100 mg of anti-human immunoglobulin G (IgG; Sigma)
per ml for 3 h.
Adenovirus construction and infection. The Z and R cDNAs were cloned into
a shuttle vector (under the control of the CMV promoter) which contains a loxP
site, the left adenovirus terminal repeat, and a packaging signal. This vector was
recombined (in a cell line expressing the phage P1 Cre protein) into the loxP site
of an adenovirus lacking the E1 and E3 genes as well as a packaging sequence to
create adenovirus-Z and adenovirus-R, as previously described (81). A control
vector (adenovirus-LacZ), containing the lacZ gene, was made in the same
manner.
HeLa cells were plated at a cell density of 106 cells per 100-mm plate. Cells
were infected with no adenovirus (mock infection), adenovirus-LacZ, adenovi-
rus-R, or adenovirus-Z at a multiplicity of infection of 50. The cells were har-
vested at 48 h postinfection.
Plasmids. The CMV-Z expression vector contains the Z cDNA downstream of
the CMV immediate-early promoter in the pHD1013 vector (64). The SV-Z
expression vector contains a genomic clone downstream of the simian virus 40
(SV40) immediate-early promoter in the SVpIE vector (25). The Z311 expres-
sion vector contains a mutation in the DNA-binding domain of Z in which amino
acid 185 is altered (abolishing DNA binding), downstream of the CMV imme-
diate-early promoter, in the pHD1013 vector (28, 42). Z86–245 (previously
referred to as RAZDR) has the codons for amino acids 2 to 86 deleted (gift of
Joseph Pagano) downstream of the CMV promoter (26). Z(S186A) contains a
genomic clone mutated at amino acid 186 downstream of the SV40 immediate-
early promoter in the SVpIE vector (25). Z25–131 has a deletion of the codons
for the first 24 amino acids of Z and is downstream of the SV40 promoter (7).
Z131–245 has a deletion of the codons for the first 130 amino acids of Z and is
downstream of the SV40 promoter (7). ZD25–42 contains the Z cDNA with a
deletion of the codons for amino acids 25 to 42 (gift of Alain Sergeant) down-
stream of the CMV immediate-early promoter in the pHD1013 vector. Zta
(m12/13), referred to as Zm12/13 in this paper, contains mutations at amino
acids 12 and 13 (from KF to AA) in the pcDL-SRa296 vector (gift of Diane
Hayward) (69). In experiments with Zm12/13, a plasmid containing wild-type Z
in the pcDL-SRa296 vector was used (69). PRTS-15 contains R downstream of
the SV40 promoter in the pSG5 vector (gift of Diane Hayward). The PML
protein vector contains the PML gene downstream of the CMV promoter in the
CMX vector (19). The HA-SUMO-1 vector contains the hemagglutinin (HA)-
tagged SUMO-1 gene downstream of the CMV promoter in the pHSS10B vector
(55).
DNA purification. Plasmid DNA was purified through Qiagen columns as
described by the manufacturer (Qiagen).
DNA transfection. DNA (20 mg) was transfected into cells by electroporation
with a Zapper electroporation unit (Medical Electronics Shop, University of
Wisconsin) at 1,500 V as described (76). All cells were resuspended in RPMI
1640 medium prior to electroporation.
Protein preparation. Cells were washed twice with phosphate-buffered saline
(PBS), resuspended in ELB buffer (0.25 M NaCl, 0.1% NP-40, 50 mM HEPES
[pH 7], 5 mM EDTA, protease inhibitors), and freeze-thawed twice. The lysed
cells were centrifuged, and the supernatant was used for immunoblot analysis.
For SUMO-1-modified proteins, the cells were washed twice with PBS and
resuspended in a 1:3 mixture of buffer I (5% sodium dodecyl sulfate [SDS], 0.15
M Tris-HCl [pH 6.8], 30% glycerol) and buffer II (25 mM Tris-HCl [pH 8.3], 50
mM NaCl, 0.5% NP-40, 0.5% deoxycholate, 0.1% SDS, and protease inhibitors).
The cells were briefly sonicated and centrifuged, and the resulting supernatant
was used for immunoblot analysis.
Immunoblot analysis. Immunoblot analysis was performed to detect the PML,
Z, and HA-SUMO-1 proteins as follows. Briefly, 10 to 100 mg of protein was
loaded in each lane, and SDS-polyacrylamide gel electrophoresis was performed.
The proteins were transferred onto nitrocellulose (Protran), blocked in 13
PBS–5% milk–0.1% Tween 20, and incubated in primary antibody for 1 to 2 h at
room temperature or overnight at 4°C (monoclonal anti-EBV Zebra [1:100] from
Argene; monoclonal anti-PML [PG-M3] [1:100] from Santa Cruz; anti-HA probe
[Y-11] [1:100] from Santa Cruz). The membrane was washed in PBS–0.1%
Tween 20, incubated in secondary antibody for 30 to 60 min at room temperature
(goat anti-mouse Ig-horseradish peroxidase [1:10,000] conjugate from Promega;
goat anti-rabbit Ig-horseradish peroxidase conjugate [1:10,000] from Promega),
and washed, and the results were visualized with the ECL chemiluminescence kit
(Amersham) according to the manufacturer’s instructions.
Immunocytochemistry. Cells were grown on glass coverslips, rinsed in 13
Tris-saline (TS; 10 mM Tris-HCl [pH 8], 150 mM NaCl), and fixed in 100%
methanol for 10 min at 220°C. The cells were then rehydrated in cold 13 TS for
5 min, incubated in incubation mix (13 TS, 0.3% bovine serum albumin [BSA],
5% goat serum) at room temperature for 10 min, incubated in primary antibody
diluted in incubation mix for 1 h at 37°C (monoclonal anti-EBV Zebra [1:50],
polyclonal anti-Z M47 [1:500], from Erik Flemington; monoclonal anti-PML
protein [PG-M3] [1:100], from Santa Cruz; polyclonal anti-PML protein
[1:1,000], from Gary Hayward; or monoclonal anti-EBV R [1:50] from Argene).
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Cells were washed four times with 13 TS–0.5% BSA for 5 min each and then
incubated in secondary antibody diluted in incubation mix for 45 min at 37°C
(goat anti-mouse Ig-fluorescein isothiocyanate conjugate [1:100], from Sigma;
goat anti-rabbit Ig-indocarbocyanine conjugate [1:100], from Jackson Labs).
Cells were washed as before, mounted in Anti-fade medium (Molecular Probes),
and viewed on a Zeiss Axioskop or Zeiss confocal microscope.
RESULTS
Lytic EBV replication disperses PML bodies. Expression of
either the EBV Z or R immediate-early protein in EBV-pos-
itive cell lines is sufficient to trigger lytic EBV replication (14,
15, 43, 65, 67, 68, 75, 81, 82). To investigate whether lytic EBV
replication induces disruption of PML bodies, we used expres-
sion vectors to express the Z and R proteins in the latently
infected EBV-positive cell line D98/HE-R1 (Fig. 1). In cells
that are positively expressing Z (Fig. 1A), there is a coincident
dispersal of PML bodies (Fig. 1B). Expression of the other
immediate-early protein, R, also induced relocalization of
PML bodies in these EBV-positive cells (Fig. 1C and D).
These experiments were repeated several times with similar
results. Therefore, lytic EBV replication induces dispersal of
PML bodies.
Z but not R expression disperses PML bodies. The two
other herpesvirus family members known to disperse PML
bodies, HSV-1 and CMV, do so via their immediate-early
proteins ICP0 and IE1, respectively (3, 23, 40, 46, 57). To
examine whether an EBV immediate-early protein is also re-
sponsible for PML body relocalization, we expressed either Z
or R in EBV-negative cells and examined the resulting PML
body distribution (Fig. 2). Expression of Z in EBV-negative
HeLa cells resulted in a redistribution of PML protein from
PML bodies to a diffuse microspeckled pattern (Fig. 2A and
B). However, expression of R in HeLa cells did not affect the
localization of PML protein (Fig. 2C and D). Additionally,
expression of the EBV early protein BMRF1 had no effect on
PML protein localization (data not shown). These experiments
were repeated several times with results identical to those
presented. Therefore, Z expression is sufficient to disrupt PML
bodies.
Transactivation domain of Z is necessary for dispersal of
PML protein. The Z protein has functional domains for tran-
scriptional transactivation, DNA binding, and homodimeriza-
tion (25, 47, 61). To determine which region(s) of the Z protein
is required for PML protein dispersal, we expressed various Z
mutants (Fig. 3) in EBV-negative HeLa cells and examined the
resulting PML protein localization (Fig. 4). Deletion of the
first half of Z (Z131–245) rendered the protein unable to
disperse PML bodies (Fig. 4C and D). More specifically, amino
acids 1 to 86 of the activation domain of Z are necessary for
PML dispersal (Fig. 4E and F). ZD25–42 retained the ability to
disperse PML bodies (Fig. 4G and H). Deletion of the first 24
amino acids of Z (Z25–245) partially but not completely
blocked the ability of the protein to disrupt PML bodies (Fig.
4I and J). Z constructs containing mutations within the DNA-
binding domain of Z, including Z311 (mutation at codon 185
which renders the protein unable to bind to DNA) and
Z(S186A) (mutation at codon 186 which prevents protein from
inducing lytic EBV replication) retained the ability to disrupt
PML bodies (Fig. 4K, L, M, and N). Therefore, amino acids 1
to 24, which were previously shown to have a replication func-
tion distinct from the Z transcriptional function (69), and the
second half of the activation domain of Z (amino acids 42 to
86) are necessary for Z to disperse PML bodies fully. However,
direct DNA binding is not required.
Z induces loss of high-molecular-weight isoforms of PML
protein. The PML protein has a molecular mass of approxi-
mately 70 kDa; however, several higher-molecular-weight iso-
forms of PML protein exist. These higher-molecular-weight
isoforms are modified by SUMO-1, a small ubiquitin-like pro-
tein that is covalently linked to PML protein (8, 66, 72). To
investigate whether Z disperses PML protein by inducing a loss
FIG. 1. EBV lytic replication disrupts PML bodies. EBV-positive cells (D98/HE-R-1) were transfected with expression plasmids for either Z
(A and B) or R (C and D). At 48 h posttransfection, cells were fixed and immunostained with either anti-Z (monoclonal) (A), anti-R (monoclonal)
(C), or anti-PML protein (polyclonal) (B and D) antibodies. Arrows indicate cells that are positively expressing Z or R.
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of SUMO-1-modified PML protein isoforms, we expressed Z
in EBV-negative A549 cells via an adenovirus construct and
performed an immunoblot with an anti-PML antibody (Fig. 5).
Cells that expressed Z but not the control protein LacZ lost the
high-molecular-weight forms of PML protein (Fig. 5). R ex-
pression did not affect PML protein levels or SUMO-1 modi-
fication. This Z-induced loss of SUMO-1-modified PML pro-
tein isoforms was also detected in other cell types, including
HeLa and D98/HE-R1 (data not shown).
Z is modified by SUMO-1. The SUMO-1 modification of
PML protein targets PML protein to nuclear bodies (60, 86).
To examine whether Z is modified by SUMO-1, we expressed
Z and HA-tagged SUMO-1 proteins in DG75 cells, harvested
these cells in a rapidly denaturing buffer which has been shown
previously to prevent loss of SUMO-1 (17), and performed
immunoblot analysis with anti-Z and anti-HA antibodies (Fig.
6A). Using these harvesting conditions, the anti-Z antibody
detected at least two larger bands (at approximately 50 and 66
kDa), and possibly a third larger band, in addition to the
normal Z band (35 kDa) (Fig. 6A, left panel, lane 3). Increas-
ing amounts of transfected HA-SUMO-1 increased the inten-
sity of these larger bands (Fig. 6A, left panel, lanes 4 to 6),
indicating that increased levels of SUMO-1 lead to increased
levels of Z/SUMO-1. To ensure that the 50 and 66-kDa Z
bands were indeed modified by the HA-SUMO-1 protein, we
probed an identical blot with anti-HA antibody (Fig. 6A, right
panel). Lanes 10 to 12 clearly show that the 50- and 66-kDa
bands are HA-SUMO-1-modified Z. These results indicate
that Z is SUMO-1 modified and that there are at least two
forms of SUMO-1-modified Z.
We subsequently used the same technique to map the do-
main(s) of Z that is required for SUMO-1 modification. As
shown in Fig. 6B, cotransfection of the HA-SUMO-1 plasmid
with a series of wild-type and mutant Z plasmids induced
SUMO-1 modification of all constructs containing the first 24
amino acids of Z but did not modify any mutant in which these
residues were deleted. Since there is only one lysine in the first
24 amino acids of Z (residue 12), we examined a Z construct
that contained mutations at amino acids 12 and 13 and found
that this mutant did not become SUMO-1 modified. There-
fore, Z is SUMO-1 modified on the lysine residing at amino
acid position 12.
Z and PML protein compete for limiting levels of SUMO-1.
As evident from Fig. 6, Z is very efficiently modified by
SUMO-1. If SUMO-1 is limiting in cells, then a protein that is
strongly modified by SUMO-1 could potentially disperse PML
protein by competing with PML protein for limiting levels of
SUMO-1 protein. To examine whether Z is able to compete
FIG. 2. Z but not R expression disrupts PML bodies. EBV-negative (HeLa) cells were transfected with expression plasmids for either Z (A and
B) or R (C and D). At 48 h posttransfection, cells were fixed and immunostained with either anti-Z (monoclonal) (A), anti-R (monoclonal) (C),
or anti-PML protein (polyclonal) (B and D) antibodies.
FIG. 3. Structures of wild-type and mutant Z proteins. The trans-
activation (hatched), DNA-binding (DNA; black), and dimerization
(dim.; stippled) domains are indicated. The amino acid (aa) numbers
are noted at the top. X, mutated amino acid.
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with PML protein for SUMO-1 modification, we expressed
PML protein and HA-SUMO-1, with or without Z, in DG75
cells. The cells were harvested so as to preserve SUMO-1
modification, and we performed immunoblot analysis with an
anti-HA antibody (Fig. 7A). The SUMO-1 modification of
PML protein was decreased in the presence of Z (compare
lanes 3 and 5), while the SUMO-1 modification of Z remained
unchanged in the presence of PML protein (compare lanes 4
and 5). When the level of cotransfected HA-SUMO-1 plasmid
was increased to 10 mg, SUMO-1 modification of PML protein
in the presence of Z was partially rescued. Additionally, the
total level of PML protein was slightly decreased by Z. A
decrease in total PML protein levels in the presence of Z is not
unexpected, however, since Fig. 7B shows that SUMO-1
FIG. 4. Mapping the region of Z required for PML body dispersion. HeLa cells were transfected with 20 mg of DNA. At 48 h posttransfection,
cells were fixed and immunostained with anti-Z (polyclonal) antibody (A, C, E, G, I, K, and M) and anti-PML protein (monoclonal) antibody (B,
D, F, H, J, L, and N). (A and B) wild-type Z. (C and D) Z131–245. (E and F) Z86–245. (G and H) ZD25–42 (I and J) Z25–245. (K and L) Z311.
(M and N) Z(S186A). Arrows point to cells that are positively expressing Z.
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greatly stabilizes PML protein. As shown in Fig. 7C, the Z
SUMO-1 modification site, lysine 12, is required for inhibition
of PML protein SUMO-1 modification. These results suggest
that the level of SUMO-1 is limiting in cells and that Z out-
competes PML protein for SUMO-1 modification.
Loss of the SUMO-1 modification site of Z does not prevent
PML body disruption. To determine if SUMO-1 modification
of Z is required for the disruption of PML bodies, we ex-
pressed the Z mutant lacking the SUMO-1 site, Zm12/13, in
HeLa cells and performed immunocytochemistry to determine
the localization of PML protein in these transfected cells (Fig.
8). Surprisingly, the Zm12/13 mutant retained the ability to
disperse PML bodies (Fig. 8B and C). These data suggest that
while competition for SUMO-1 may play a role in Z-induced
PML body dispersion, Z must also use another mechanism to
disperse PML bodies.
Induction of lytic replication in Akata cells leads to rapid
SUMO-1 modification of Z. To examine whether lytic replica-
tion would yield levels of SUMO-1-modified Z comparable to
the levels obtained with transfected plasmids, we induced
EBV-positive Akata cells to undergo lytic replication via cross-
linking of the surface IgG by anti-IgG. Three hours after in-
duction, the cells were harvested so as to preserve SUMO-1
modification, and immunoblot analysis was performed with an
anti-Z antibody (Fig. 9). While control cells (no anti-IgG) did
not express Z, the anti-IgG-treated cells expressed Z as well as
higher-molecular-weight forms of Z corresponding to SUMO-
1-modified species. Therefore, physiological levels of Z and
SUMO-1 are sufficient to produce high levels of SUMO-1-
modified Z.
DISCUSSION
The EBV immediate-early protein Z is required for expres-
sion of the EBV early genes and plays an essential role in
replication mediated through the lytic origin of replication
(oriLyt). In addition to these direct roles in lytic viral replica-
tion, increasing evidence suggests that Z manipulates the host
cell environment through a variety of different mechanisms,
presumably to provide favorable conditions for viral replica-
tion. For example, Z inhibits cell cycle progression (12), acti-
vates the p38 kinase and c-Jun N-terminal kinase signaling
cascades (1), and alters p53 (84) and CBP function (2). Here
we show that the Z protein also induces dispersion of nuclear
PML bodies, an ability it shares with at least two other imme-
diate-early proteins in the herpesvirus family.
PML body dispersion by Z requires amino acids 1 through
86, containing the Z transactivation domain and an essential
replication function, and is associated with loss of PML protein
SUMO-1 modification. We also found that Z is SUMO-1 mod-
ified over residue 12, suggesting that SUMO-1 modification
may play a role in targeting Z to specific domains within the
nucleus or moderating its stability or protein-protein interac-
tions. SUMO-1 modification of Z may also provide a mecha-
nism for PML body dispersion, since Z competes with PML
protein for SUMO-1. However, unmodified Z retains the abil-
ity to disperse PML bodies, indicating that another mechanism
must also exist for PML body dispersion. Given that deletion of
amino acids 1 to 86 totally prevents dispersal of PML bodies by
Z while deletion of amino acids 1 to 25 only partially prevents
dispersion, it appears that the transcriptional activator region
of Z encodes a function (as yet undefined) required for full
PML body dispersion.
PML bodies have become an increasingly intense area of
study because, although their specific function remains uncer-
tain, they clearly play an important role in tumor suppression.
PML bodies are made up of several proteins, some of which
have known functions (CBP and Rb), and some of which have
unknown functions (Sp100 and PML protein). Since some of
the components are transcriptional regulators and PML pro-
tein itself is structurally similar to a transcription factor, it has
been suggested that PML bodies play a role in regulating
cellular transcription. Although PML bodies themselves are
devoid of any nucleic acid, nucleic acids can be found along
their periphery (9).
SUMO-1 is another component of PML bodies. SUMO-1 is
found covalently attached to at least two PML body proteins,
PML and Sp100. Although structurally similar to ubiquitin,
SUMO-1 does not target proteins for degradation. Instead,
SUMO-1 stabilizes proteins and can act to guide them to their
appropriate locations within the nucleus. The SUMO-1 mod-
ification of PML protein appears to be of utmost importance—
PML protein must be SUMO-1 modified in order to reside
within PML bodies, and if PML protein is not present in these
bodies, other PML body members do not localize properly
(86). Therefore, PML protein seems to be the main organizer
of the PML body.
We have demonstrated in this study that EBV lytic replica-
tion disperses PML bodies, transforming nuclear dots into tiny
microspeckles. When either immediate-early protein, Z or R,
is expressed in cells latently infected with EBV, PML protein
becomes dispersed, presumably because expression of either
protein activates the entire EBV lytic cascade. In EBV-positive
cells, the redistributed protein appears to form larger aggre-
gates than in EBV-negative cells, potentially due to the for-
mation of EBV replication centers containing PML protein
(11). However, in EBV-negative cells, only Z is capable of
FIG. 5. Z expression induces a loss of PML protein isoforms. EBV-
negative A549 cells were mock infected (lane 1) or infected with an
adenovirus expressing either LacZ (lane 2), Z (lane 3), or R (lane 4).
Cells were harvested 48 h postinfection, and Western blot analysis was
performed with anti-PML protein monoclonal antibody. PML iso-
forms lost after Z expression are indicated by asterisks.
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dispersing PML bodies. Therefore, R likely indirectly disperses
PML bodies in EBV-positive cells by activating the expression
of Z.
Our data show that Z is SUMO-1 modified and that at least
two different SUMO-1-modified isoforms exist. Since the
SUMO-1 modification of PML protein is responsible for its
localization into discrete nuclear bodies, SUMO-1 modifica-
tion may likewise target Z to PML bodies. We have been
unable to show that Z colocalizes with PML bodies (data not
shown). However, it is possible that transient localization of Z
into PML bodies does occur prior to the disruption of PML
bodies.
In many respects, our findings here are reminiscent of pre-
vious reports regarding the effects of HSV-1 and CMV on
PML bodies. In the case of HSV-1, the immediate-early pro-
tein ICP0, like Z, disperses PML bodies. In cells infected with
intact HSV, new nuclear foci appear after PML bodies are
disrupted, and these new foci function as HSV-1 replication
compartments that contain HSV-1 replication proteins as well
as PML protein (11). This suggests a role for PML protein in
viral replication. CMV also disrupts PML bodies shortly after
infection. In the case of CMV, the IE1 protein is targeted to
and disperses PML bodies, possibly through a mechanism in-
volving direct protein-protein interactions between IE1 and
PML protein (3). In contrast, the CMV IE2 protein is also
targeted to but does not disperse PML bodies. Similar to
HSV-1, CMV replication compartments (which contain IE2 as
well as several other essential viral replication proteins) sub-
sequently form adjacent to the former PML bodies (5).
Another striking similarity is the ability of all three viruses
HSV-1, CMV, and EBV to decrease the relative amount of the
SUMO-1-modified forms of PML protein. Although the exact
mechanisms by which herpesvirus immediate-early proteins
reduce the abundance of SUMO-1-modified PML protein re-
mains unknown, in the case of HSV-1, at least, this process can
be reversed by proteosome inhibitors (13, 22), suggesting that
HSV-1 preferentially activates degradation of SUMO-modi-
fied PML protein. In contrast, we did not find that proteosome
inhibitors reverse the effect of Z on PML protein SUMO-1
modification (unpublished data).
It is intriguing that both the Z and CMV IE1 proteins are
SUMO-1 modified. Thus, if any component of the SUMO-1
FIG. 6. Z is modified by SUMO-1. (A) EBV-negative DG75 cells were transfected with vector, HA-SUMO-1 (10 mg), Z (10 mg), or Z (10 mg)
plus HA-SUMO-1 (1, 5, or 10 mg) expression plasmids. Cells were harvested 48 h posttransfection using conditions which preserve SUMO-1
modification, and Western blot analysis was performed with anti-Z (monoclonal) (left panel) or anti-HA (right panel) antibodies. Arrowheads
indicate HA-SUMO-1-modified Z proteins. (B) EBV-negative DG75 cells were transfected with 5 mg of HA-SUMO-1 plus 10 mg of either vector,
Z, Zm12/13, Z25–245, Z131–245, ZD25–42, or Z86–245 expression plasmids. Zm12/13 contains mutations that alter amino acids 12 and 13 (69).
Cells were harvested 48 h posttransfection using conditions which preserve SUMO-1 modification, and Western blot analysis was performed with
anti-HA (monoclonal) (top panel) or anti-Z (bottom panel) antibodies.
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modification machinery is limiting in cells, one potential mech-
anism by which Z (and CMV IE1) could inhibit SUMO-1
modification of PML protein would be through direct compe-
tition for a limiting factor, similar to the ability of the adeno-
virus E1A protein to prevent histone acetylation of cellular
genes by direct competition for CBP/p300. Against this hypoth-
esis is the finding that the CMV IE1 protein (which, in contrast
to Z, interacts directly with the PML protein) inhibits SUMO
modification of only a limited number of known SUMO-1
substrates (13, 22, 59). However, Z appears to be a highly
efficient substrate for SUMO-1 modification, even though the
Z SUMO-1 modification site (DVKFT) does not conform to
the previously reported consensus sequence (I/L)KxE (73).
Indeed, in cells cotransfected with Z and SUMO-1 expression
vectors, Z appears to be the major SUMO-1-modified protein
in the host cell (Figs. 6 and 7), and Z competed with PML
FIG. 7. Z competes with PML protein for SUMO-1. (A) EBV-negative DG75 cells were transfected with vector, HA-SUMO-1 (10 mg), PML
protein (10 mg) plus HA-SUMO-1 (2 mg), Z (10 mg) plus HA-SUMO-1 (2 mg), or Z (10 mg) plus PML protein (10 mg) plus HA-SUMO-1 (2 or
10 mg) expression plasmids. Cells were harvested 48 h posttransfection, and Western blot analysis was performed with anti-HA antibody (upper
panel). The blot was reprobed with anti-PML protein monoclonal antibody to check for total PML protein levels (lower panel). (B) EBV-negative
DG75 cells were transfected with vector, HA-SUMO-1 (10 mg), PML protein (5 mg), or PML protein (5 mg) plus HA-SUMO-1 (2 mg). Cells were
harvested 48 h posttransfection, and Western blot analysis was performed with an anti-PML protein monoclonal antibody. (C) EBV-negative
DG75 cells were transfected with HA-SUMO-1 along with either vector, PML, Z, Z plus PML protein, or Zm12/13 plus PML protein expression
plasmids. Ten micrograms of each plasmid was used. Cells were harvested 48 h posttransfection, and Western blot analysis was performed with
anti-HA antibody (upper panel). The blot was reprobed with anti-PML protein monoclonal antibody to check for total PML protein levels (lower
panel).
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protein for cotransfected SUMO-1. Alternatively, since phos-
phorylation of the PML protein has been shown to inhibit
SUMO-1 modification (60), Z could potentially prevent PML
protein SUMO-1 modification by increasing the level of PML
protein phosphorylation.
To our knowledge, Z (in addition to CMV IE1 and IE2) is
only the third viral protein shown to be SUMO-1 modified. As
discussed above, SUMO-1 modification of Z, like PML pro-
tein, could potentially be important for its localization to PML
bodies. Alternatively, SUMO-1 modification could affect the
stability of Z or its interactions with other proteins. Mutation
of the two SUMO-1 modification sites in the CMV IE2 protein
was recently shown to inhibit its transcriptional function with-
out affecting protein stability or nuclear localization (35).
Given the increasing evidence that PML bodies regulate tran-
scription in the cell, it is interesting that the domain of Z
required for full PML body dispersion (amino acids 1 through
86) is also known to be required for Z transcriptional function
(25). An increasing number of important cellular transcrip-
tional proteins, including CBP, p53, Ap-1, Rb, Daxx, and Sp1,
have been shown to be regulated by their interactions with
PML bodies. Similarly, in the HSV-1 ICP0 protein, small mu-
tations in the RING finger domain which disrupt the ability of
ICP0 to disperse PML bodies considerably decrease the ability
of ICP0 to transcriptionally activate early HSV-1 promoters
and decrease viral replication by 10- to 100-fold (21). The
ability of Z to disperse PML bodies may likewise be important
for its transcriptional function and/or its well-described ability
to modulate the activity of cellular transcription factors such as
CBP and p53 (2, 83, 84).
At this point it remains unknown whether lytic EBV infec-
tion, like HSV-1 and CMV infection, also incorporates PML
protein into replication foci. The Hayward group has shown
that a specific mutation affecting only residues 12 and 13 in Z
impairs Z replication function but not transactivator function
(69). As shown here, this mutation also prevents SUMO-1
modification of Z. Thus, SUMO-1 modification of Z may well
play a role in lytic EBV replication.
Increasing evidence suggests that a variety of PML protein-
dependent functions in the cell would be inhibitory to viral
replication in the host. Most importantly, PML protein is re-
quired for apoptosis induced by several different types of stim-
uli, including interferon (27, 50), and for inducing MHC class
I presentation (85). The fact that so many different viruses
encode mechanisms to disrupt PML body function suggests
that this protein may have a profoundly important role in vivo
for controlling viral infection.
FIG. 8. Z mutant that cannot be SUMO modified disperses PML bodies. HeLa cells were transfected with 20 mg of DNA. At 48 h
posttransfection, cells were fixed and immunostained with anti-Z polyclonal antibody (A and C) and anti-PML protein monoclonal antibody (B
and D). (A and B) Wild-type Z. (C and D) Zm12/13.
FIG. 9. Z is SUMO-1 modified in Akata cells after induction with
anti-IgG cross-linking. Akata cells were induced to undergo lytic rep-
lication via anti-IgG cross-linking for 3 h. Cells were harvested using
conditions which preserve SUMO-1 modification, and Western blot
analysis was performed with anti-Z polyclonal antibody. The open
arrowhead indicates unmodified Z; the solid arrowhead indicates
SUMO-1-modified Z.
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